Compare ORIC & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORIC | VINP |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 638.8M |
| IPO Year | 2020 | 2020 |
| Metric | ORIC | VINP |
|---|---|---|
| Price | $12.04 | $9.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 2 |
| Target Price | ★ $19.73 | $14.00 |
| AVG Volume (30 Days) | ★ 1.0M | 43.5K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 5.72% |
| EPS Growth | ★ 19.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $18.07 |
| Revenue Next Year | N/A | $12.74 |
| P/E Ratio | ★ N/A | $24.41 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.23 | $9.19 |
| 52 Week High | $14.93 | $13.61 |
| Indicator | ORIC | VINP |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 47.63 |
| Support Level | $10.67 | $9.40 |
| Resistance Level | $12.57 | $10.26 |
| Average True Range (ATR) | 0.60 | 0.30 |
| MACD | -0.25 | -0.00 |
| Stochastic Oscillator | 0.84 | 39.19 |
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.